03:49:04 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-03-28 Årsstämma 2024
2024-02-15 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-03 Kvartalsrapport 2023-Q1
2023-03-29 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-12-09 Extra Bolagsstämma 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-19 Ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-12-29 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-30 Kvartalsrapport 2020-Q1
2019-12-20 Extra Bolagsstämma 2019
2019-06-27 Årsstämma 2019
2019-06-03 Ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriMedicinteknik
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo.
2022-10-26 07:00:00
OSLO - October 26, 2022: SoftOx Solutions AS ("SoftOx" or the "Company"), a
medtech and clinical-stage pharmaceutical company based in Oslo, Norway, today
announces its results for the third quarter of 2022.

"In the third quarter of 2022, SoftOx achieved two major milestones: the
selection of our technology by the European Defence Fund (EDF) to develop
countermeasures against CBRN threats and the end of the Phase 1 study evaluating
the safety and tolerability of the SoftOx Biofilm Eradicator. Both
accomplishments were years in the making and represent the persistence,
expertise and commitment of the SoftOx team."

"The company is in an opportune position to initiate and continue talks with
European and international market players. We are now focused on ending the year
with successful clinical results and continue exploring opportunities to develop
our exciting platform technology," said Geir Almås, Chief Executive Officer of
SoftOx Solutions.

Operational highlights
o SoftOx announced the early completion of the Phase 1 SBE-01 trial, with
positive results of the SoftOx Biofilm Eradicator (SBE) in treating chronic
wounds. SBE was demonstrated to be safe and well tolerated as well as reducing
the bacterial burden and improving wound healing in chronic leg wounds.
o SoftOx received final approval on biocidal products application for hand and
surface disinfection from the Swedish Chemicals Agency (KemI). This approval
allows SoftOx to sell its disinfection products in Sweden.
o The SoftOx technology, through its subsidiary SoftOx Defense Solutions (SDS),
was granted NOK 97 million from the European Defence Fund to develop a military
inhalation solution for the EU and its allies as part of a pan-European
consortium.
o SDS's leadership team was strengthened with the addition of Jørgen Berggrav as
Senior Advisor and Johan Christian Harstad as Project Director.

Financial highlights
(Figures in brackets represent the corresponding period in 2021 unless states
otherwise)
o Q3 pre-tax results ended with a loss of NOK 23,7 million (loss of 22 million).
Results are characterized by high levels of activity in research and
development.
o Total operating expenses for the third quarter were NOK 25.3 million (NOK 23,4
million)
o Cash and cash equivalents amounted to NOK 3.2 million at the end of the second
quarter (NOK 16.6 million)
o In October, SoftOx secured a convertible loan from existing shareholders for
NOK 25 million and refinanced the NOK 15 million convertible loan as reported on
28 June 2022.


Presentation details
The results will be presented by the management via webcast at 09:00 (CET).

To register for the presentation, click the following link:

https://teams.microsoft.com/registration/GPWsOGT7vUCuf-It04UbWQ,oEPfirp3r0GbFmWN
BzTZNg,ebnx2uZTkE2EPvewJm782g,A7wyP47zO0yXrzMTR20aXA,QniapSBGZ0urCimjTSRqIw,ziH9
X8hk9U2QqA8bEDZFxg?mode=read&tenantId=38acf518-fb64-40bd-ae7f-e22dd3851b59

The presentation will be held in English and followed by a Q&A session.

For any questions or interview requests, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Kristine Rød, CFO at SoftOx Solutions AS
Mail: ir@soft-ox.com Phone:
Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a medtech and
clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of
reducing the spread of infection and emergence of antimicrobial resistance. For
more information on SoftOx, visit www.soft-ox.com